AAAAAA

   
Results: 1-10 |
Results: 10
The intronic G13964C variant in p53 is not a high-risk mutation in familial breast cancer in Australia
Authors: Marsh, A Spurdle, AB Turner, BC Fereday, S Thorne, H Pupo, GM Mann, GJ Hopper, JL Sambrook, JF Chenevix-Trench, G
Citation: A. Marsh et al., The intronic G13964C variant in p53 is not a high-risk mutation in familial breast cancer in Australia, BREAST CA R, 3(5), 2001, pp. 346-349
A single nucleotide polymorphism in the 5 ' untranslated region of RAD51 and risk of cancer among BRCA1/2 mutation carriers
Authors: Wang, WW Spurdle, AB Kolachana, P Bove, B Modan, B Ebbers, SM Suthers, G Tucker, MA Kaufman, DJ Doody, MM Tarone, RE Daly, M Levavi, H Pierce, H Chetrit, A Yechezkel, GH Chenevix-Trench, G Offit, K Godwin, AK Struewing, JP
Citation: Ww. Wang et al., A single nucleotide polymorphism in the 5 ' untranslated region of RAD51 and risk of cancer among BRCA1/2 mutation carriers, CANC EPID B, 10(9), 2001, pp. 955-960
The microsomal epoxide hydrolase Tyr113His polymorphism: Association with risk of ovarian cancer
Authors: Spurdle, AB Purdie, DM Webb, PM Chen, XQ Green, A Chenevix-Trench, G
Citation: Ab. Spurdle et al., The microsomal epoxide hydrolase Tyr113His polymorphism: Association with risk of ovarian cancer, MOL CARCINO, 30(1), 2001, pp. 71-78
No significant association between progesterone receptor exon 4 Val660Leu G/T polymorphism and risk of ovarian cancer
Authors: Spurdle, AB Webb, PM Purdie, DM Chen, XQ Green, A Chenevix-Trench, G
Citation: Ab. Spurdle et al., No significant association between progesterone receptor exon 4 Val660Leu G/T polymorphism and risk of ovarian cancer, CARCINOGENE, 22(5), 2001, pp. 717-721
Polymorphisms at the glutathione S-transferase GSTM1, GSTT1 and GSTP1 loci: risk of ovarian cancer by histological subtype
Authors: Spurdle, AB Webb, PM Purdie, DM Chen, XQ Green, A Chenevix-Trench, G
Citation: Ab. Spurdle et al., Polymorphisms at the glutathione S-transferase GSTM1, GSTT1 and GSTP1 loci: risk of ovarian cancer by histological subtype, CARCINOGENE, 22(1), 2001, pp. 67-72
CYP17 promoter polymorphism and breast cancer in Australian women under age forty years
Authors: Spurdle, AB Hopper, JL Dite, GS Chen, XQ Cui, JS McCredie, MRE Giles, GG Southey, MC Venter, DJ Easton, DF Chenevix-Trench, G
Citation: Ab. Spurdle et al., CYP17 promoter polymorphism and breast cancer in Australian women under age forty years, J NAT CANC, 92(20), 2000, pp. 1674-1681
Androgen receptor exon 1 CAG repeat length and risk of ovarian cancer
Authors: Spurdle, AB Webb, PM Chen, XQ Martin, NG Giles, GG Hopper, JL Chenevix-Trench, G
Citation: Ab. Spurdle et al., Androgen receptor exon 1 CAG repeat length and risk of ovarian cancer, INT J CANC, 87(5), 2000, pp. 637-643
CYP17 promotor polymorphism and ovarian cancer risk
Authors: Spurdle, AB Chen, XQ Abbazadegan, M Martin, N Khoo, SK Hurst, T Ward, B Webb, PM Chenevix-Trench, G
Citation: Ab. Spurdle et al., CYP17 promotor polymorphism and ovarian cancer risk, INT J CANC, 86(3), 2000, pp. 436-439
Androgen receptor exon 1 CAG repeat length and breast cancer in women before age forty years
Authors: Spurdle, AB Dite, GS Chen, XQ Mayne, CJ Southey, MC Batten, LE Chy, H Trute, L McCredie, MRE Giles, GG Armes, J Venter, DJ Hopper, JL Chenevix-Trench, G
Citation: Ab. Spurdle et al., Androgen receptor exon 1 CAG repeat length and breast cancer in women before age forty years, J NAT CANC, 91(11), 1999, pp. 961-966
Utilisation of predictive, prenatal and diagnostic testing for Huntington's disease in Johannesburg
Authors: Kromberg, JGR Krause, A Spurdle, AB Temlett, JA Lucas, M Rodseth, D Stevens, G Jenkins, T
Citation: Jgr. Kromberg et al., Utilisation of predictive, prenatal and diagnostic testing for Huntington's disease in Johannesburg, S AFR MED J, 89(7), 1999, pp. 774-778
Risultati: 1-10 |